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Ku80 is a subunit of the Ku heterodimer that binds to DNA double-strand break ends 
as part of the non-homologous end joining (NHEJ) pathway. Ku80 is also involved in 
homologous recombination (HR) via its interaction with BRCA1. Ku80 is encoded by 
the XRCC5 gene that contains a variable number tandem repeat (VNTR) insertion in its 
promoter region. Different VNTR genotypes can alter XRCC5 expression and affect Ku80 
production, thereby affecting NHEJ and HR pathways. VNTR polymorphism is associated 
with multiple types of sporadic cancer. In this study, we investigated its potential associa-
tion with familial breast cancer at the germline level. Using PCR, PAGE, Sanger sequenc-
ing, and statistical analyses, we compared VNTR genotypes in the XRCC5 promoter 
between healthy individuals and three types of familial breast cancer cases: mutated 
BRCA1 (BRCA1+), mutated BRCA2 (BRCA2+), and wild-type BRCA1/BRCA2 (BRCAx). 
We observed significant differences of VNTR genotypes between control and BRCA1+ 
group (P < 0.0001) and BRCA2+ group (P = 0.0042) but not BRCAx group (P = 0.2185), 
and the differences were significant between control and cancer-affected BRCA1+ cases 
(P < 0.0001) and BRCA2+ cases (P = 0.0092) but not cancer-affected BRCAx cases 
(P = 0.4251). Further analysis indicated that 2R/2R (OR = 1.94, 95%CI = 1.26–2.95, 
P = 0.0096) and 2R/1R (OR = 1.58, 95%CI = 1.11–2.26, P = 0.0388) were associ-
ated with increased risk but 1R/1R (OR = 0.55, 95%CI = 0.35–0.84, P = 0.0196) and 
1R/0R (OR = 0, 95%CI = 0–0.29, P = 0.0012) were associated with decreased risk in 
cancer-affected BRCA1+ group; 2R/1R (OR = 1.94, 95%CI = 1.14–3.32, P = 0.0242) 
was associated with increased risk in cancer-affected BRCA2+ group. No correlation 
was observed for the altered risk between cancer-affected or -unaffected carriers and 
between different age of cancer diagnosis in cancer-affected carriers. The frequently 
Abbreviations: BRCA1, breast cancer 1, early onset; BRCA2, breast cancer 2, early onset; BRCAx, familial breast cancer with 
wild type BRCA1 and BRCA2; HR, homologous recombination; NHEJ, non-homologous end joining; PAGE, polyacrylamide 
gel electrophoresis; VNTR, variable number tandem repeat.
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inTrODUcTiOn
Breast cancer is the major cancer type in women. Up to 20% of 
breast cancer cases have familial genetic background, with multi-
ple family members across generations affected by the disease (1). 
The discovery of the germline mutations in BRCA1 and BRCA2 
confirmed the presence of genetic predisposition for familial 
breast cancer (2–4). These genes maintain genome stability in 
normal cells by repairing double-strand breaks mainly through 
homologous recombination (HR) pathway; their mutated forms 
lead to genome instability and increased risk for breast cancer 
development (5). There are two types of DNA double-strand break 
repair mechanisms: non-homologous end joining (NHEJ) and 
HR (6). Deficiency in the HR pathway, mainly caused by BRCA 
germline mutations, is well known to increase the risk of breast 
cancer (7); however, it is not equally clear whether deficiency in 
NHEJ pathway can also increase breast cancer risk (8).
Ku is a heterodimer consisting of Ku80 encoded by XRCC5 
and Ku70 encoded by XRCC6. Ku recognizes DNA double-strand 
break ends to initiate the NHEJ pathway, and Ku can also affect 
the function of the HR pathway by interacting with BRCA1 
(9–13). Deletion of XRCC5 in mice leads to increased chromo-
somal instability, immune deficiency, growth retardation, and 
cancer (14, 15). Altered expression of XRCC5 promotes onco-
genic phenotypes, including hyper proliferation and resistance 
to apoptosis, genomic instability, and tumorigenesis (16), and 
has been observed in various types of sporadic cancer, including 
bladder, breast, colorectal, skin, esophageal, gastric, head, and 
neck cancer (17–22).
Variable number tandem repeats (VNTRs) are tandem 
repeat DNA sequences often located in gene regulatory regions 
that can influence gene expression (23–25). VNTRs follow 
a Mendelian pattern of inheritance. The XRCC5 promoter 
contains a VNTR at −160  bp, with a 21-bp repetitive unit 
(TGCGCATGCTCGGCGGGAATC) hosting a putative Sp1-
binding site (26). Studies in Chinese and Iranian populations 
have demonstrated the presence of VNTR alleles ranging from 0 
to 3 21-bp tandem repeats (0R, 1R, 2R, and 3R), with individual 
genotypes of 0R/0R, 1R/0R, 1R/1R, 2R/0R, 2R/1R, 2R/2R, 3R/0R, 
3R/1R, and 3R/2R (22, 23). Experimental data indicate that the 
number of VNTR repeats is inversely related to XRCC5 expres-
sion, with an increase in the number of VNTR repeats linked to 
decreased XRCC5 expression (27–29) (Figure 1A). VNTR poly-
morphisms in the XRCC5 promoter are associated with sporadic 
bladder, gastric, and breast cancer (30–32).
Given the transmission pattern of VNTR, the uncertainty 
regarding the role of NHEJ in familial breast cancer, the pres-
ence of VNTR polymorphisms in the XRCC5 promoter, and 
the association of VNTR polymorphisms with sporadic cancer, 
we hypothesized that VNTR in the XRCC5 promoter could be 
involved in familial breast cancer. Therefore, we screened germline 
VNTR polymorphisms in the XRCC5 promoter in three types 
of familial breast cancer (BRCA1+, BRCA2+, and BRCAx). The 
results showed that certain genotypes of VNTR polymorphisms 
are associated with the risk of familial breast cancer in BRCA1+ 
and BRCA2+ carriers.
MaTerials anD MeThODs
study Population
The familial breast cancer cases used in this study included three 
subtypes: familial breast cancer with BRCA1 mutation (BRCA1+), 
familial breast cancer with BRCA2 mutation (BRCA2+), and 
familial breast cancer without BRCA1 or BRCA2 mutations 
(BRCAx). Samples were obtained from the Hereditary Cancer 
Center at Creighton University (Tables S1–S3 in Supplementary 
Material). Healthy control samples of age- and gender-matched, 
de-identified Caucasian individuals were obtained from the 
Nebraska Biobank of the University of Nebraska Medical Center 
and The Nebraska Medical Center. The use of patient samples 
for this study was approved by the Institutional Review Board of 
Creighton University School of Medicine (00-12265) and of the 
University of Nebraska Medical Center (718-11-EP). Written and 
informed consent to participate in the study and to publicate the 
results was obtained from all subjects.
genotyping VnTr Polymorphisms in the 
XRCC5 Promoter
PCR amplification, PAGE gel separation, and Sanger sequenc-
ing were used to determine VNTR genotype in the XRCC5 
promoter of each patient. PCR primer sequences were based 
on a previously published study (22) with sense primer 
5′AGGCGGCTCAAACACCACAC3′ and antisense primer 
5′CAAGCGGCAGATAGCGGAAAG3′. The PCR mixture con-
sisted of DNA (20 ng), sense and antisense primers (10 pmol), 
and GoTaqH DNA polymerase (2 U, Promega). The PCR cycling 
conditions were 7 min at 95°C; 35 cycles of 30 s at 95°C, 30 s at 
62°C, and 45 s at 72°C; and a final extension of 7 min at 72°C. 
An 8% PAGE gel was used to separate PCR products to deter-
mine allele type and genotype in each case (3R allele = 287 bp; 
2R allele = 266 bp; 1R allele = 245 bp; and 0R allele = 224 bp). 
Representative products were isolated from PAGE gels and vali-
dated by Sanger sequencing.
VnTr genotypes in the XRCC5 Promoter 
of caucasians
Data from Iranian and Chinese healthy populations showed that 
VNTR genotypes in the XRCC5 promoter can vary between 
ethnic groups (27, 28). To determine whether the data from 
observed VNTR association with in BRCA1+ and BRCA2+ breast cancer group indicates 
that VNTR polymorphism in the XRCC5 promoter is associated with altered risk of breast 
cancer in BRCA1+ and BRCA2+ carriers.
Keywords: Ku80, XRCC5, promoter, VnTr, familial breast cancer, BRCA1, BRCA2, association
FigUre 1 | VnTr in XRCC5 promoter. (a) VNTR types and position in the promoter of XRCC5. The VNTR is located at −160 bp, with 3R, 2R, 1R, and 0R 
alleles. Arrows refer to PCR primers used to amplify the VNTR region for genotyping. It also shows higher copies of VNTR lead to lower XRCC5 expression (21–23). 
(B) Size distribution of different VNTR genotypes. PCR products of different genotypes were separated on an 8% PAGE gel. 2R/2R and 1R/1R had single band, 
other were heterozygotes with two bands, of which 2R/1R, 1R/0R, and 3R/2R had 21-base differences, and 3R/1R and 2R/0R had 42-base differences; (c) Sanger 
sequencing validation of 1R/1R and 2R/2R genotypes. It shows the 21-base unit (TGCGCATGCTCGGCGGGAATC) in 1R, and 42-base unit in 2R. 3R/3R DNA was 
not available for sequencing due to its rarity in human population.
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these healthy populations can be used as suitable healthy controls 
for our study in breast cancer of Caucasian cases, we tested the 
genotypes of 100 healthy local Caucasian individuals and com-
pared these with the genotypes from 535 Caucasian Iranian and 
235 Chinese populations (27). The results showed no significant 
difference in genotypes between the local and Iranian Caucasian 
populations (P = 0.3774) with 2R/2R, 2R/1R, and 1R/1R as the 
major genotypes, but a significant difference was seen in the 
genotypes between local Caucasian and Chinese populations 
(P < 0.0001), and Iranian Caucasian and Chinese (P < 0.0001), 
whose genotypes included 2R/2R, 2R/1R, 2R/0R, 1R/1R, 1R/0R, 
and 0R/0R (Table 1). The 535 Iranian cases were from a Caucasian 
population living in the Fars province of Iran (27). Because these 
Iranian cases and our local cases were of the same ethnicity and 
TaBle 2 | summary of the BRCA1+, BRCA2+, and BRCAx carriers used in 
the study*.
items BRCA1+ BRCA2+ BRCAx
Unaffected cases 60 29 11
Average current age 56.9 ± 14.4 49.1 ± 14.4 66.4 ± 15.8
Affected cases 166 69 89
Average age at diagnosis 41.4 ± 10.8 43.6 ± 10.3 47.7 ± 12.0
Proband 38 15 62
Non-proband 128 54 27
Breast cancer 166 69 89
ER 22(+)43(−) 17(+)8(−) 27(+)6(−)
Unknown 101 44 56
PR 17(+)45(−) 15(+)9(−) 21(+)9(−)
Unknown 104 45 59
HER2/neu 4(+)10(−) 3(+)4(−) 6(+)17(−)
Unknown 152 62 66
Lymph nodes 38(+)54(−) 16(+)23(−) 16(+)16(−)
Unknown 74 30 57
Left 56 17 24
Right 55 25 27
Bilateral 40 19 8
Unknown 15 8 30
Adenocarcinoma not 
specified
28 7 17
Ductual carcinoma 89 43 59
Lobular carcinoma 4 4 4
Medullary carcinoma 24 3
Mucoid or colloid carcinoma 3
Unknown 21 12 6
Invasive 148 63 79
In situ 5 2 3
Both invasive and in situ 6 3 3 
Unknown 7 1 4
Ovarian cancer 21 5 15
Left 1
Right 3
Bilateral 4 1 2
Unknown 14 4 12
Fallopian tube 1 1
Lymph nodes 7(+)10(−) 1(+) 2(+)3(−)
Unknown 4 4 10
Carcinoma, not specified 3 4
Clear cell adenocarcinoma 1 1
Papillary adenocarcinoma 2 2 1
Adenocarcinoma 
(cystadenocarcinoma)
9 1 1
Endometrioid 
adenocarcinoma
2
Serous (cyst)
adenocarcinoma
5 1 3
Dysgerminoma 1
Unknown 1 5
Invasive 20 5 9
In situ 1 1
Unknown 5
*Some number in categories may not add up to the total due to incompleteness of 
tested cases.
TaBle 1 | genotype distribution in three ethnical populations.
genotype local iranian chinese
3R/2R 0 (0) 4 (1) 0 (0)
3R/1R 1 (1) 8 (1) 0 (0)
3R/0R 1 (1) 1 (0) 0 (0)
2R/2R 16 (16) 84 (16) 28 (12)
2R/1R 50 (50) 205 (38) 57 (24)
2R/0R 5 (5) 29 (5) 71 (30)
1R/1R 22 (22) 168 (31) 12 (5)
1R/0R 5 (5) 33 (6) 37 (16)
0R/0R 0 (0) 3 (1) 30 (13)
Total 100 (100) 535 (100) 235 (100)
P value Local to Iranian: 0.3774
Local to Chinese: <0.0001
Iranian to Chinese: <0.0001
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there were no significant differences in genotypes between the 
two groups, the genotypes of the 100 local cases and the 535 
Iranian cases were combined to make up the control population 
for downstream analyses. The combined control group is at 
Hardy-Weinberg equilibrium (X2 = 4.3485, df = 6, P = 0.6296).
statistical analyses
Fisher’s exact test was applied to determine the differences of 
VNTR polymorphism between the groups of familial breast can-
cer populations and control population, each type of breast cancer 
and cancer-affected and -unaffected subgroups within each type 
of cancer. Both odds ratios and their 95% confidence intervals and 
P-values were computed by using exact methods to keep consist-
ency (33). Benjamini and Hochberg method was used to control 
the false positive rate at 0.05 (34). Analyses were performed using 
SAS® software version 9.4 (SAS Institute Inc., Cary, NC, USA).
resUlTs
samples Used in the study
BRCA1+ carrier refers to the women who tested positive for a 
pathogenic BRCA1 mutation; BRCA2+ refers to the women who 
tested positive for a pathogenic BRCA2 mutation; and BRCAx 
refers to the women who tested negative for the mutations in 
BRCA1, BRCA2, and p53, with two or more first or second degree 
relatives affected with primary in  situ or invasive breast, ovar-
ian, fallopian tube, or peritoneal cancer, and at least one person 
must have negative test result. Under each group, the cases were 
further divided into breast cancer (ovarian cancer)-affected and 
-unaffected carriers. The average ages at breast cancer diagnosis 
among the groups were 41.4 (BRCA1+), 43.6 (BRCA2+), and 47.7 
(BRCAx). The age distributions are consistent with existing data 
that BRCA1 and BRCA2 mutation carriers tend to suffer cancer 
at earlier age. Most of the breast cancers were ductal type and 
ER-positive; all, but one, of the cases of ovarian cancer were 
invasive at diagnosis (Table 2).
VnTr genotypes in the XRCC5 Promoter
The four VNTR alleles in the XRCC5 promoter consist of three 21-bp 
(TGCGCATGCTCGGCGGGAATC) tandem repeats (3R), two 
21-bp repeats (2R), one 21-bp repeat (1R), or without repeat (0R). 
The combination of PCR, PAGE, and Sanger sequencing methods 
provided an effective means to determine VNTR genotypes formed 
TaBle 3 | genotype distribution in three types of familial breast cancer.
genotype control Familial 
breast cancer
BRCA1+ BRCA2+ BRCAx
Total 635 (100) 226 (100) 98 (100) 100 (100)
3R/2R 4 (1) 0 (0) 0 (0) 0 (0)
3R/1R 9 (1) 2 (1) 0 (0) 0 (0)
3R/0R 2 (0) 0 (0) 0 (0) 0 (0)
2R/2R 100 (16) 61 (27) 27 (28) 23 (23)
2R/1R 255 (40) 113 (50) 51 (52) 48 (48)
2R/0R 34 (5) 4 (2) 1 (1) 3 (3)
1R/1R 190 (30) 45 (20) 17 (17) 19 (19)
1R/0R 38 (6) 1 (0) 2 (2) 7 (7)
0R/0R 3 (0) 0 (0) 0 (0) 0 (0)
P value <0.0001 0.0042 0.2185
TaBle 4 | genotypes between cancer-affected and unaffected familial breast cancer.
genotype control BRCA1+ BRCA2+ BRCAx
cancer no cancer cancer no cancer cancer no cancer
Total 635 (100) 166 (100) 60 (100) 69 (100) 29 (100) 89 (100) 11 (100)
3R/2R 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
3R/1R 9 (1) 2 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
3R/0R 2 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
2R/2R 100 (16) 44 (27) 17 (28) 17 (25) 10 (34) 20 (22) 3 (27)
2R/1R 255 (40) 85 (51) 28 (47) 39 (57) 12 (41) 41 (46) 6 (64)
2R/0R 34 (5) 3 (2) 1 (2) 0 (0) 1 (3) 3 (3) 0 (0)
1R/1R 190 (30) 32 (19) 13 (22) 13 (19) 4 (14) 18 (20) 1 (9)
1R/0R 38 (6) 0 (0) 1 (2) 0 (0) 2 (7) 7 (8) 0 (0)
0R/0R 3 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
P value <0.0001 0.2216 0.0092 0.2748 0.4251 0.5664
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by the four alleles. Figure 1B shows the genotypes of homozygotes 
(1R/1R and 2R/2R) and heterozygotes (3R/2R, 3R/1R, 2R/1R, 
2R/0R, and 1R/0R), and Figure  1C shows the sequences of the 
21-bp repeats from the homozygotes (1R/1R and 2R/2R).
VnTr genotype Distribution, BRCA 
Predisposition, and cancer status
We compared the VNTR genotype distributions in the XRCC5 
promoter between three types of familial breast cancer: BRCA1+, 
BRCA2+, and BRCAx (Tables S1–S3 in Supplementary Material). 
The results show that the BRCA1+ and BRCA2+ groups differed 
significantly from the control group (BRCA1+ group: P < 0.0001; 
BRCA2+ group: P =  0.0042), but no difference was observed 
between the BRCAx groups and control group (P  =  0.1308) 
(Table 3). To test whether different VNTR genotype distribution 
exists relating to disease status, the three types of familial breast 
cancer were divided into breast cancer-affected and breast cancer-
unaffected subgroups and further compared each subgroup with 
the control group. The results show that the differences were only 
present between the cancer-affected subgroups in both groups 
of BRCA1+ (cancer-affected: P  <  0.0001, cancer-unaffected: 
P = 0.2216) and BRCA2+ (cancer-affected: P = 0.0092, cancer-
unaffected: P  =  0.2748), but not in BRCAx (cancer-affected: 
P = 0.4251, cancer-unaffected: P = 0.5664) (Table 4). These results 
suggest the presence of association between VNTR genotypes and 
BRCA1 and BRCA2 mutation carriers affected with breast cancer.
We also compared the genotypes between the affected and 
unaffected subgroups in each group, and observed no difference 
in between (Table 5). We also evaluated the relationship between 
ages at diagnosis and VNTR polymorphism and observed no 
significant relationship in all three groups (data not shown). 
Therefore, there is no relationship between age of disease, cancer 
status, and VNTR polymorphism.
specific genotypes associated with risk 
of Familial Breast cancer
Through comparing between control, breast cancer-affected and 
breast cancer-unaffected groups, we tested odds ratio to identify 
specific genotypes associated with risk of breast cancer (Table 6). 
Considering that the 3R and 0R groups contain only few cases in 
both control and carrier population, we removed 3R/2R, 3R/1R, 
3R/0R, 2R/0R, and 0R/0R but focused on the 2R/2R, 2R/1R, 
1R/1R, and 1R/0R as they contributed most of the cases. The 
results showed that
 1. BRCA1+ group. 2R/2R (OR  =  1.94, 95%CI  =  1.26–2.95, 
P =  0.0096) and 2R/1R (OR  =  1.58, 95%CI  =  1.11–2.26, 
P  =  0.0388) were associated with increased risk of breast 
cancer in cancer-affected BRCA1+ group, and 1R/1R 
(OR =  0.55, 95%CI  =  0.35–0.84, P =  0.0196) and 1R/0R 
(OR = 0, 95%CI = 0–0.29, P = 0.0012) were associated with 
the decreased risk in cancer-affected BRCA1+ group;
 2. BRCA2+ group. 2R/1R (OR  =  1.94, 95%CI  =  1.14–3.32, 
P =  0.0242) was associated with increased risk in cancer-
affected BRCA2+ group. 2R/2R, 1R/1R, and 1R/0R had no 
association with the risk in cancer-affected BRCA2+ group;
 3. BRCAx group. 2R/2R, 2R/1R, 1R/1R, and 1R/0R had no asso-
ciation with the risk of breast cancer in breast cancer-affected 
BRCAx group.
DiscUssiOn
Gene regulatory regions have long been considered a potential 
source of “missing heritability” in cancer (35, 36). Our study 
provides evidence showing that VNTR polymorphisms in the 
TaBle 6 | association of VnTr genotypes in XRCC5 promoter with familial breast cancer-affected and -unaffected groups.
genotype control affected 
case
Odds 
ratio
95% ci P-value adjusted Unaffected 
case
Odds 
ratio
95% ci P-value adjusted
BRCA1+
2R/2R 100 45 1.94 1.26–2.95 0.0016 0.0096 16 2.09 1.05–3.97 0.0221 0.1326
2R/1R 255 87 1.58 1.11–2.26 0.0087 0.0388 26 1.25 0.69–2.23 0.3190 0.4785
1R/1R 190 32 0.55 0.35–0.84 0.0049 0.0196 13 0.69 0.33–1.35 0.2906 0.4978
1R/0R 38 0 0 0–0.29 0.0001 0.0012 1 0.28 0.01–1.73 0.2414 0.5794
BRCA2+
2R/2R 100 17 1.75 0.97–3.15 0.0865 0.1038 10 2.82 1.13–6.58 0.0174 0.2088
2R/1R 255 39 1.94 1.14–3.32 0.0101 0.0242 12 1.05 0.45–2.38 1 1
1R/1R 190 13 0.54 0.27–1.04 0.0680 0.0907 4 0.37 0.09–1.11 0.0632 0.1896
1R/0R 38 0 0 0–0.73 0.0427 0.0641 2 1.16 0.13–4.93 0.6916 0.7545
BRCAx
2R/2R 100 20 1.55 0.90–2.67 0.1101 1 3 2.01 0.52–7.69 0.3945 0.5257
2R/1R 255 41 1.27 0.84–1.82 0.2882 0.3096 6 1.79 0.54–5.92 0.3654 0.5481
1R/1R 190 18 0.59 0.35–1.02 0.0583 0.3168 1 0.23 0.03–1.84 0.1885 0.5655
1R/0R 38 7 1.34 0.58–3.10 0.4913 1 0 0 0–4.75 1 1
TaBle 5 | comparison between affected and unaffected group.
genotype affected case Unaffected case Odds ratio 95% ci P-value adjusted
BRCA1+
2R/2R 45 16 0.9299 0.46–1.96 0.8637 0.9422
2R/1R 87 26 1.265 0.66–2.42 0.5403 1
1R/1R 32 13 0.7906 0.37–1.79 0.5664 1
1R/0R 0 1 0 0–64.08 0.2522 1
BRCA2+
2R/2R 17 10 0.769 0.27–2.26 0.6281 0.9422
2R/1R 39 12 1.8417 0.70–4.91 0.1904 1
1R/1R 13 4 1.3929 0.38–6.45 0.7707 1
1R/0R 0 2 0 0–1.44 0.0854 1
BRCAx
2R/2R 20 3 0.77 0.19–3.19 0.7118 0.9350
2R/1R 41 6 0.71 0.20–2.50 0.5951 1
1R/1R 18 1 2.54 0.30–21.12 0.6850 1
1R/0R 7 0 Infinity 0.23–infinity 1 1
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XRCC5 promoter is associated with risk of familial breast cancer 
with BRCA1+ and BRCA2+ predisposition. Data from sporadic 
breast cancer showed that 2R/1R was not associated (OR = 1.09, 
95%CI = 0.78–1.53, P = 0.595), but 0R/0R was associated with 
the disease (OR = 9.55, 95%CI = 1.19–76.6, P = 0.034) (31). The 
different results suggest that the association of VNTR polymor-
phisms in the XRCC5 promoter differs between familial breast 
cancer and sporadic breast cancer.
For the BRCA1+ and BRCA2+ groups, the results can be 
explained by synergistic roles between Ku80 and BRCA1/BRCA2 
in maintaining genome stability through the NHRJ and HR path-
ways (37–39). Altered expression of Ku80 can disturb the synergy 
resulting in increased breast cancer risk in BRCA mutation carri-
ers. The results also suggest that genotype 1R/1R and 1R/0R can 
reduce the risk of breast cancer in BRCA1+ carriers. Based on 
current knowledge, it is difficult to relate VNTR polymorphisms 
to BRCAx familial breast cancer, as genetic predisposition in 
this heterogeneous group of familial breast cancer remains to be 
determined. We did not observe a relationship between age at 
onset of disease, cancer status, and VNTR polymorphism. This 
could be due to the weaker influence by the VNTR polymor-
phism compared with that of the BRCA mutation predisposition. 
Alternatively, it could be due to the limited sample size used in the 
study, which restricts the statistical power to detect the potential 
significance. Further studies with larger sample size will help to 
address the issue.
In summary, our study indicates that 2R/2R and 2R/1R were 
significantly associated with increased risk, and 1R/1R and 1R/0R 
were significantly associated with the decreased risk of BRCA1+ 
breast cancer, whereas 2R/1R was significantly associated with 
the increased risk of BRCA2+ breast cancer.
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